Literature DB >> 22403285

Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets.

Alexander W Pastuszak1, Harsha Mittakanti, Joceline S Liu, Lissette Gomez, Larry I Lipshultz, Mohit Khera.   

Abstract

Subcutaneous testosterone (T) pellets are a viable treatment modality for hypogonadism. Optimal dosing, frequency of reimplantation, and long-term safety of T pellets remain incompletely elucidated parameters. A retrospective review of 273 patients treated for hypogonadism using subcutaneous T pellets was performed. Serum total T (TT), free T (FT), and estradiol (E2) levels were analyzed as a function of time from implantation, number of pellets implanted (6-9 or 10-12), body mass index (BMI; <25 or ≥ 25 kg/m(2)), number of implantations (≤ 4 rounds, 501 insertions), and preimplantation T levels (<300 or ≥ 300 ng/dL). T decay was determined using linear regression and TT levels immediately postimplantation and the time for TT levels to reach 300 ng/dL extrapolated for all variables. Mean patient age ± SD was 56 ± 12.6 years. Baseline TT level was 328 ± 202 ng/dL, FT 9.49 ± 27.8 pg/mL, and E2 25.1 ± 17.3 pg/mL. Extrapolated TT and FT peaks were lower in men receiving 6 to 9 pellets than men receiving 10 to 12, although decay rates differed insignificantly. E2 levels rose significantly in men receiving 10 to 12 but not 6 to 9 pellets. Men with BMI ≥ 25 kg/m(2) attained lower TT peaks with slower decay than men with BMI <25 kg/m(2) receiving 10 to 12 pellets, although 300 ng/dL TT levels were reached at approximately 100 days in both groups. No differences were seen in decay rates for men with multiple implant rounds, and no differences in T peaks or decay rates were seen in men with preimplant T level <300 or ≥ 300 ng/dL. One patient developed erythrocytosis, and no prostate-specific antigen recurrences were observed in men with prostate cancer treated with T pellets. Men with BMI <25 kg/m(2) should receive fewer pellets, and reimplantation for all men should occur 100 to 120 days after prior implantation. Men receiving 10 to 12 pellets have higher E2 levels, potentially reflecting increased aromatization of T. Reimplantation and preimplantation TT levels do not affect pellet decay kinetics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22403285     DOI: 10.2164/jandrol.111.016295

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  12 in total

1.  An update on male hypogonadism therapy.

Authors:  Prasanth Surampudi; Ronald S Swerdloff; Christina Wang
Journal:  Expert Opin Pharmacother       Date:  2014-04-23       Impact factor: 3.889

Review 2.  Erythrocytosis Following Testosterone Therapy.

Authors:  Samuel J Ohlander; Bibin Varghese; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2017-05-16

Review 3.  Testosterone therapy in children and adolescents: to whom, how, when?

Authors:  Maria Camila Suarez A; Joseph M Israeli; Eliyahu Kresch; Leon Telis; Daniel E Nassau
Journal:  Int J Impot Res       Date:  2022-01-07       Impact factor: 2.896

Review 4.  Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age.

Authors:  Alexander W Pastuszak; Marc Gittelman; James P Tursi; Jonathan S Jaffe; David Schofield; Martin M Miner
Journal:  Andrology       Date:  2021-10-08       Impact factor: 4.456

Review 5.  Alternative treatment modalities for the hypogonadal patient.

Authors:  Landon W Trost; Mohit Khera
Journal:  Curr Urol Rep       Date:  2014-07       Impact factor: 3.092

6.  Patient satisfaction with testosterone replacement therapies: the reasons behind the choices.

Authors:  Jason R Kovac; Saneal Rajanahally; Ryan P Smith; Robert M Coward; Dolores J Lamb; Larry I Lipshultz
Journal:  J Sex Med       Date:  2013-11-06       Impact factor: 3.802

7.  Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen.

Authors:  Alexander W Pastuszak; Lissette P Gomez; Jason M Scovell; Mohit Khera; Dolores J Lamb; Larry I Lipshultz
Journal:  Sex Med       Date:  2015-08-12       Impact factor: 2.491

Review 8.  A Review of Testosterone Pellets in the Treatment of Hypogonadism.

Authors:  Andrew McCullough
Journal:  Curr Sex Health Rep       Date:  2014

Review 9.  Adult-onset hypogonadism: evaluation and role of testosterone replacement therapy.

Authors:  Andrew J Davidiuk; Gregory A Broderick
Journal:  Transl Androl Urol       Date:  2016-12

Review 10.  Diagnosis and management of testosterone deficiency.

Authors:  James A McBride; Culley C Carson; Robert M Coward
Journal:  Asian J Androl       Date:  2015 Mar-Apr       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.